博士，教授，博士生導師，“藥明康德生命化學研究獎”獲得者。
基本介紹
- 中文名：王淼
- 國籍：中國
- 畢業院校：浙江大學 、北京協和醫學院
- 教學職稱：教授
個人簡介,研究領域,著作譯作,科研成果,專利,發表論文,
個人簡介
王淼博士，1996年畢業於浙江大學生物科學與技術系，1999年於浙江大學獲得動物生理生化方向碩士學位，2002年於北京協和醫學院獲得免疫學方向博士學位。在美國賓夕法尼亞大學(University of Pennsylvania)藥理系從事博士後研究，獲得美國賓夕法尼亞大學醫學院臨床研究認證（ 臨床流行病學與生物統計學）。2006年起先後擔任賓夕法尼亞大學藥理系做研究助理（Research Associate）和研究助理教授（Research Assistant Professor）。 2010起受聘為美國輝瑞製藥全球研發(Pfizer Global R&D) 心血管與代謝性疾病研發部主要科學家(Principal Scientist)。2013年就職於中國醫學科學院/北京協和醫學院國家心臟病中心心血管疾病國家重點實驗室和阜外醫院臨床藥理中心。長期從事心血管疾病分子機制與藥物發現研究。
研究領域
緊密圍繞疾病防治的臨床需要，運用分子細胞生物學、遺傳學和影像學手段，整合疾病動物模型研究與臨床研究，探討冠心病及相關併發症的發病機制，並探索其可能的臨床套用。目前研究集中於（1）心血管疾病的炎症免疫調節機制；（2）新藥靶的功能鑑定與新藥發現。
著作譯作
王淼、樊朝美合著《抗血栓治療—新藥與治療策略》2018年科學出版社出版，ISBN：9787030386267。
科研成果
專利
靶向CXCR7的藥物組合物和方法（申請號：2018800084588，發明人：王淼、郝會峰、陳虹）
遺傳工程化的非人類哺乳動物及其構建方法和套用（申請號：2018800280719，發明人：王淼、陳虹）
靶向前列腺素E2及其受體的藥物與套用（申請號：2018800280189，發明人：王淼、郝會峰、胡昇）
磷酸二酯酶4抑制劑的用途（申請號：2020103481969，發明人：王淼、萬青、徐傳勝）
發表論文
發表主要論文於Nature Communications， PNAS，Circulation （2008， 2011， 2017），J Clin Invest，Arterioscler Thromb Vasc Biol，J Pharmacol Exp Ther等學術期刊。
(1)Zhu L, Xu C, Huo X, Hao H, Wan Q, Chen H, Zhang X, Breyer RM, Huang Y, Cao X, Liu DP, FitzGerald GA, Wang M * (*Corresponding author). The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury. Nature Communications. 2019 Apr 23;10(1):1888.
(2) Hao H, Hu S, Chen H, Bu D, Zhu L, Xu C, Chu F, Huo X, Tang Y, Sun X, Ding B, Liu D, Hu S, Wang M* (*Corresponding author). Loss of Endothelial CXCR7 Impairs Vascular Homeostasis, and Cardiac Remodeling After Myocardial Infarction: Implications for Cardiovascular Drug Discovery. Circulation. 2017; 135(13):1253-1264.
(3) Hao H, Hu S, Wan Q, Xu C, Chen H, Zhu L, Xu Z, Meng J, Breyer RM, Li N, Liu DP, FitzGerald GA, Wang M* (*Corresponding author). Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury. Arterioscler Thromb Vasc Biol. 2018;38(5):1115-1124.
(4)Wang M* (*Corresponding author), Hao H, Leeper NJ, Zhu L. Thrombotic Regulation From the Endothelial Cell Perspectives. Arterioscler Thromb Vasc Biol. 2018;38(6):e90-e95.
(5) Wang M* (*Corresponding author), Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L, Grant G, Cheng Y, Lawson JA, Assoian RK, Jones PL, Fitzgerald GA*. Microsomal Prostaglandin E2 Synthase-1 Modulates the Response to Vascular Injury. Circulation. 2011;123(6):631-9.
(6) Wang M, Lee E, Song W-L, Ricciotti E, Rader DJ, Lawson JA, Puré E and FitzGerald GA. Microsomal PGE Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin II Induced Abdominal Aortic Aneurysm Formation. Circulation, 2008;117(10):1302-9.
(7) Hui Y, Crichton I, Ricciotti E, Yu Z, Wang D, Stubbe J, Wang M, Puré E, FitzGerald GA. Targeted Deletions of COX-2 and Atherogenesis in Mice. Circulation. 2010;121(24):2654-60
(8) Knight DR, Smith AH, Schroeder RL, Huang C, Beebe DA, Sokolowski SA, Wang M* (*Corresponding author). Effects of age on noninvasive assessments of vascular function in nonhuman primates: implications for translational drug discovery. Journal of Translational Medicine. 2013, 11:101 doi:10.1186/1479-5876-11-101
(9) Wang M* (*Corresponding author), Jin W, Guo AM, Stubbe J. Cardiovascular Inflammation. Mediators of Inflammation. 2013, 11:101. doi: 10.1155/2013/123513.
(10) Lowell AN, Qiao H, Liu T, Ishikawa T, Zhang H, Oriana S, Wang M, Ricciotti E, FitzGerald GA, Zhou R, and Yamakoshi Y. Functionalized Low-Density Lipoprotein Nanoparticles for in Vivo Enhancement of Atherosclerosis on Magnetic Resonance Images. Bioconjugate Chem. 2012; 23(11):2313-9.
(11) Wang M* (*Corresponding author), Jiang M, Cooper PR, Zhao H, Hui Y, Yao Y, Tate JC, Damera G, Lawson JA., Jester WF, Panettieri RA and FitzGerald GA. Deletion of microsomal Prostaglandin E Synthase does not alter ozone-induced airway hyper-responsiveness. J Pharmacol Exp Ther. 2010;334(1):63-8
(12) Damera G, Zhao H, Wang M, Smith M, Kirby C, Jester WF, Lawson JA, Panettieri RA Jr. Ozone modulates IL-6 secretion in human airway epithelial and smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009;296(4):L674-83.
(13) Wang Y, Barthold J, Figueroa E, González R, Noh PH, Wang M, Manson J. Analysis of five single nucleotide polymorphisms in the ESR1 gene in cryptorchidism. Birth Defects Res A Clin Mol Teratol. 2008;82(6):482-5
(14) Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA. Tetranor PGDM: An abundant urinary metabolite reflects biosynthesis of PGD2 in mice and humans. J Biol Chem. 2008;283(2):1179-88.
(15)Song WL, Lawson JA, Wang M, Zou H, FitzGerald GA. Noninvasive Assessment of the Role of Cyclooxygenases in Cardiovascular Health: A Detailed HPLC/MS/MS Method. Methods in Enzymol. 2007;433:51-72.
(16) Cheng Y, Wang M (co-first authorship), Yu Y, Lawson JA, Funk CD and FitzGerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116(5):1391-9.
(17) Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E and FitzGerald GA. Deletion of microsomal PGE synthase -1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A. 2006; 103(39):14507-12.
(18)Wang D, Wang M, Cheng Y, FitzGerald GA. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol. 2005, 5(2):204-10.
(19)Egan KM, Wang M, Lucitt MB, Zukas AM, Puré E, Lawson JA and FitzGerald GA. Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism. Circulation, 2005, 111(3): 334-342
